Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

531042 Estrogen Receptor Antagonist, ICI 182,780 - CAS 129453-61-8 - Calbiochem

531042
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
129453-61-8C₃₂H₄₇F₅O₃S

Products

Catalogue NumberPackaging Qty/Pack
5310420001 Glass bottle 10 mg
Description
OverviewA cell-permeable estradiol derivative that acts as an estrogen antagonist and down-regulates estrogen receptors without affecting estrogen receptor-mediated progesterone receptor expression. Hence, it lacks estrogen agonist activity. Shown to be more effective than tamoxifen in reducing estrogen receptors in breast tumor cells. Suppresses the growth of MCF-7 xenografts in mice for twice as long as tamoxifen and delays tumor growth.

Please note that the molecular weight for this compound is batch-specific due to variable water content.
Catalogue Number531042
Brand Family Calbiochem®
SynonymsGPR30 Agonist, ICI 182,780, ICI 182780, ICI182780
References
ReferencesWakeling, A. E., et al. 1991. Cancer Res. 51, 3867.
Dauvois, S., et al. 1993. J. Cell. Sci. 106, 1377.
Howell, A., et al. 1995. The Lancet. 8941, 29.
Robertson, J.F., et al. 2001. J. Steroid Biochem. Mol Biol. 79, 209.
Product Information
CAS number129453-61-8
DeclarationSold with the permission of AstraZeneca UK. Limited for research purposes only.
FormWhite powder
Hill FormulaC₃₂H₄₇F₅O₃S
Chemical formulaC₃₂H₄₇F₅O₃S
ReversibleY
Quality LevelMQ100
Applications
Biological Information
Primary TargetER
Secondary targetGPR30
Purity≥98% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped at Ambient Temperature or with Blue Ice or with Dry Ice
Toxicity Standard Handling
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
5310420001 04055977242515

Documentation

Estrogen Receptor Antagonist, ICI 182,780 - CAS 129453-61-8 - Calbiochem SDS

Title

Safety Data Sheet (SDS) 

References

Reference overview
Wakeling, A. E., et al. 1991. Cancer Res. 51, 3867.
Dauvois, S., et al. 1993. J. Cell. Sci. 106, 1377.
Howell, A., et al. 1995. The Lancet. 8941, 29.
Robertson, J.F., et al. 2001. J. Steroid Biochem. Mol Biol. 79, 209.
Data Sheet

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision29-August-2014 JSW
SynonymsGPR30 Agonist, ICI 182,780, ICI 182780, ICI182780
DescriptionA cell-permeable estradiol derivative that acts as an estrogen antagonist and down-regulates estrogen receptors without affecting estrogen receptor-mediated progesterone receptor expression. Hence, it lacks estrogen agonist activity. Shown to be more effective than tamoxifen in reducing estrogen receptors in breast tumor cells. Suppresses the growth of MCF-7 xenografts in mice for twice as long as tamoxifen and delays tumor growth.

Please note that the molecular weight for this compound is batch-specific due to variable water content.
FormWhite powder
Intert gas (Yes/No) Packaged under inert gas
CAS number129453-61-8
Chemical formulaC₃₂H₄₇F₅O₃S
Purity≥98% by HPLC
SolubilityDMSO (100 mg/ml)
Storage Protect from light
+2°C to +8°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Standard Handling
ReferencesWakeling, A. E., et al. 1991. Cancer Res. 51, 3867.
Dauvois, S., et al. 1993. J. Cell. Sci. 106, 1377.
Howell, A., et al. 1995. The Lancet. 8941, 29.
Robertson, J.F., et al. 2001. J. Steroid Biochem. Mol Biol. 79, 209.